Diagnosis and treatment of multiple postoperative fistulas following resection of a giant abdominal mesenteric fibromatosis: a case report and literature review - Takeaways - MDSpire

Diagnosis and treatment of multiple postoperative fistulas following resection of a giant abdominal mesenteric fibromatosis: a case report and literature review

  • By

  • Weihua Zheng

  • Junjie Lu

  • Shuai Jiang

  • Fan Zhang

  • Long Xia

  • Junjing Zhang

  • June 2, 2026

  • 0 min

Share

  • 1

    Mesenteric fibromatosis (MF) is a rare, locally aggressive tumor with a high postoperative recurrence rate and no metastatic potential.

  • 2

    The patient experienced rapid tumor progression and developed intestinal obstruction despite targeted therapy and immunotherapy.

  • 3

    Postoperative complications included multiple fistulas, which required a multidisciplinary team approach for effective management.

  • 4

    The patient underwent a complex surgical procedure, resulting in significant bowel resection and the creation of a high-output stoma.

  • 5

    Nutritional support transitioned from total parenteral nutrition to enteral nutrition, ultimately allowing the patient to tolerate oral feeding.

Original Source(s)

Diagnosis and treatment of multiple postoperative fistulas following resection of a giant abdominal mesenteric fibromatosis: a case report and literature review

  • by Weihua Zheng, Junjie Lu, Shuai Jiang, Fan Zhang, Long Xia, Junjing Zhang

  • June 2, 2026

Related Content

This Week’s CGT News: Base Editing Takes Aim at Cholesterol

Verve reports phase 1 data for one-time PCSK9 base editing; plus: neuroprotective gene therapy, non-viral DNA delivery, tumour-activated CAR-T, and in vivo CAR-M

  • June 1, 2026

  • 5 min
Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death

High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

  • by

  • June 1, 2026

  • 4 min
Case Report: Cytokeratin-positive interstitial reticulum cell tumor with HLA loss of heterozygosity